Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202802 | 0.91 | ADRA1D (0.46) | CD274GRIN1GRIN2BADRA1DADRA1A | |
| SCHEMBL8202799 | 0.91 | ADRA1D (0.46) | CD274GRIN1GRIN2BADRA1DADRA1A | |
| SCHEMBL8202807 | 0.91 | ADRA1D (0.46) | CD274GRIN1GRIN2BADRA1DADRA1A | |
| SCHEMBL8199718 | 0.82 | SLC6A9 (0.53) | GRIN1GRIN2BCCR5SLC18A3 | |
| SCHEMBL8199717 | 0.82 | SLC6A9 (0.53) | GRIN1GRIN2BCCR5SLC18A3 | |
| SCHEMBL6490328 | 0.82 | SLC6A9 (0.53) | GRIN1GRIN2BCCR5SLC18A3 | |
| SCHEMBL8198774 | 0.78 | GRIN1 (0.58) | GRIN1GRIN2BADRA1DADRA1AADRA1B | |
| SCHEMBL8198773 | 0.78 | GRIN1 (0.58) | GRIN1GRIN2BADRA1DADRA1AADRA1B | |
| SCHEMBL8198776 | 0.78 | GRIN1 (0.58) | GRIN1GRIN2BADRA1DADRA1AADRA1B | |
| SCHEMBL8199368 | 0.76 | CYP26A1 (0.49) | CD274ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | CD274 1144/4885GRIN1 400/4885GRIN2B 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.